Checkpoint Capital L.P. Acquires Shares of 825,341 TScan Therapeutics, Inc. (NASDAQ:TCRX)

Checkpoint Capital L.P. bought a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the third quarter, HoldingsChannel reports. The firm bought 825,341 shares of the company’s stock, valued at approximately $4,110,000. TScan Therapeutics makes up about 2.0% of Checkpoint Capital L.P.’s holdings, making the stock its 9th biggest holding.

Several other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP bought a new position in TScan Therapeutics during the second quarter worth $70,000. MetLife Investment Management LLC raised its holdings in shares of TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of TScan Therapeutics in the 2nd quarter worth about $90,000. SG Americas Securities LLC bought a new position in shares of TScan Therapeutics in the 3rd quarter worth about $78,000. Finally, American Century Companies Inc. boosted its holdings in shares of TScan Therapeutics by 48.9% in the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after buying an additional 15,596 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of TScan Therapeutics stock in a transaction on Monday, September 23rd. The stock was bought at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the transaction, the director now owns 45,000 shares of the company’s stock, valued at $238,050. The trade was a 12.50 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.76% of the stock is owned by insiders.

TScan Therapeutics Price Performance

TCRX stock opened at $4.77 on Monday. The stock has a market cap of $254.58 million, a PE ratio of -4.50 and a beta of 0.79. The firm’s 50-day simple moving average is $5.06 and its 200 day simple moving average is $6.20. TScan Therapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, sell-side analysts predict that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TCRX shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 12th. Finally, Wedbush reissued an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Tuesday, November 5th.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.